Laboratorios Farmaceuticos ROVI SA
MAD:ROVI

Watchlist Manager
Laboratorios Farmaceuticos ROVI SA Logo
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
Watchlist
Price: 72.8 EUR -1.62% Market Closed
Market Cap: €3.7B

Operating Margin

22.1%
Current
Declining
by 4.5%
vs 3-y average of 26.6%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
22.1%
=
Operating Income
€160.1m
/
Revenue
€724.2m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
22.1%
=
Operating Income
€160.1m
/
Revenue
€724.2m

Peer Comparison

Country Company Market Cap Operating
Margin
ES
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
3.7B EUR
Loading...
US
Eli Lilly and Co
NYSE:LLY
954.4B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
547B USD
Loading...
CH
Roche Holding AG
SIX:ROG
268.4B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.9B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
265.9B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
147.8B USD
Loading...
FR
Sanofi SA
PAR:SAN
94.4B EUR
Loading...

Market Distribution

Higher than 76% of companies in Spain
Percentile
76th
Based on 751 companies
76th percentile
22.1%
Low
-2 951.2% — 4.9%
Typical Range
4.9% — 19.6%
High
19.6% — 143.7%
Distribution Statistics
Spain
Min -2 951.2%
30th Percentile 4.9%
Median 12%
70th Percentile 19.6%
Max 143.7%

Laboratorios Farmaceuticos ROVI SA
Glance View

Laboratorios Farmacéuticos ROVI SA has carved a niche for itself in the pharmaceutical industry through its focus on researching, developing, manufacturing, and marketing a broad range of small molecule drugs and specialized products. Founded in Spain, ROVI has channeled its efforts towards creating innovative solutions in the healthcare sector, with heparin-based products emerging as a cornerstone of its portfolio. The company's operational model is built on vertical integration, allowing it to control the entire lifecycle of its offerings, from production to commercialization. This approach not only ensures quality and compliance with stringent regulatory standards but also enables ROVI to adapt nimbly to market demands and leverage its proprietary science to secure a competitive edge. The revenue streams of ROVI are diversified across its proprietary products, contract manufacturing services, and its portfolio of licensed products. A significant portion of revenue stems from its commitment to injectable drug products like Bemiparin, a low molecular weight heparin, which has found a foothold in various international markets. Moreover, ROVI capitalizes on partnerships and alliances with major pharmaceutical giants, augmenting its contract manufacturing capabilities and tapping into more extensive distribution networks. Not resting on its laurels, ROVI invests heavily in research and development to fortify its pipeline with innovative formulations, thus ensuring sustained growth and a resilient positioning in the global pharmaceutical landscape. This blend of strategic partnerships, internal innovation, and market-responsive production underscores ROVI's business model and revenue generation prowess.

ROVI Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
22.1%
=
Operating Income
€160.1m
/
Revenue
€724.2m
What is Laboratorios Farmaceuticos ROVI SA's current Operating Margin?

The current Operating Margin for Laboratorios Farmaceuticos ROVI SA is 22.1%, which is below its 3-year median of 26.6%.

How has Operating Margin changed over time?

Over the last 3 years, Laboratorios Farmaceuticos ROVI SA’s Operating Margin has decreased from 30.2% to 22.1%. During this period, it reached a low of 22.1% on Sep 30, 2025 and a high of 31.3% on Dec 31, 2022.

Back to Top